secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2022-09-16T23:59:59+00:00
Accession:  0001104659-22-100852
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora Pharmaceuticals names Melissa Tosca EVP of Finance; shareholders approve warrant share issuance
--------------------------------------------------------------------------------

- Melissa Tosca appointed EVP of Finance effective Sept 13, 2022; will serve as principal accounting and financial officer.
- Tosca receives $300K base salary, target bonus up to 25%, and option to purchase 300,000 shares vesting over 3 years.
- Stockholders approved issuance of up to 60,191,394 shares upon exercise of Class A and B Warrants from July 2022 offering.
- Ratified EisnerAmper as independent auditor for FY2022; adjournment proposal also approved but not needed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000110465922100852/0001104659-22-100852-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000110465922100852/tm2226014d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-100852

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer